Latest News
Madrigal Pharmaceuticals, Inc.
- Madrigal Pharmaceuticals: The Market Is Grading A Launch, Not A Self-Funding Franchise
- Madrigal Pharmaceuticals, Inc. News — BX:YDO1
- Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026
- Madrigal Pharmaceuticals shifts to self-funding with strong Q2 sales and growing patient base for Rezdiffra.
- BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says
- Madrigal Pharmaceuticals (NasdaqGS:MDGL) Stock Forecast & Analyst Predictions
- Did Genetic Response Data Just Shift Madrigal Pharmaceuticals (MDGL) Investment Narrative?
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- McCormick highlights research funding while touring Madrigal Pharmaceuticals
- McCormick highlights research funding while touring Madrigal Pharmaceuticals
- Why Zealand, AstraZeneca, and Madrigal chose Massachusetts
- Goldman Sachs assumes Madrigal Pharmaceuticals stock with buy rating
Headlines from the last 30 days, linking to the original publishers. See all market news →